Table 2. Study population demographics, host genetics and multi-clade gag recognition.
| PTID | Annual CD4 slope | Gag IFN-γ | Infecting clade Determined from Gag | Age | Gender | Mean Log10vL | HLA-A | HLA-B | HLA-C | |||
| A | B | C | D | |||||||||
| RP1 | −114.1 | D | 30.5 | F | 5.77 | A*36, A*74 | B*45, B*72, Bw*06 | Cw*2, Cw*6 | ||||
| RP2 | −102.3 | nd | 41.5 | F | 5.90 | A*02, A*68 | B*07, B*45, Bw*06 | Cw*7, Cw*16 | ||||
| RP3 | −116.0 | nd | 26.5 | F | 6.34 | A*02, A*74 | B*08, B*45, Bw*06 | Cw*7, Cw*16 | ||||
| RP4 | −101.5 | D | 25.5 | F | 5.18 | A*2301, A*6601 | B*4501, B*5802, Bw*04, Bw*06 | Cw*0602 | ||||
| RP5 | −113.3 | + | D | 41.5 | F | 5.58 | A*33, A68 | B*42, B*49, | Cw*07, Cw*17 | |||
| RP6 | −116.4 | + | A | 43.5 | F | 4.84 | A*3002, A*33 | B*1510, B*5101/05 | Cw*03, Cw*04 | |||
| RP7 | −106.1 | + | + | nd | 28.5 | F | 4.65 | A*3004/06, A*8001 | B*1401, B*1801/03/05/08, | Cw*0202, Cw*0302/06 | ||
| SP1 | +43.7 | nd | 28.5 | F | 3.96 | A*3401, A*6601 | B*4403, B*8101, Bw*4/*6, Bw*6 | Cw*0401, Cw*0701 | ||||
| SP2 | +16.3 | + | + | + | + | D | 39.5 | F | 4.97 | A*0201/*0209, A*2301 | B*0801, B*4501 Bw*06 | Cw*10, Cw*16 |
| SP3 | +22.0 | + | + | + | D | 48.5 | F | 3.79 | A*2902 | B*57, B*5801 | Cw*04, Cw*07 | |
| SP4 | +37.7 | A | 33.5 | M | 2.69 | A*02, A*30 | B*57, B*58 | Cw*04, Cw*06 | ||||
| SP5 | +26.1 | + | + | A | 35.5 | F | 4.18 | A*6601, A*7401/*7402 | B*5301, B*5802, Bw*4, Bw*6 | Cw*0401, Cw*0602 | ||
| SP6 | +20.9 | + | + | D | 29.5 | F | 4.52 | A*2301, A*3601 | B*5301, B*3910, Bw*4, Bw*6 | Cw*04, Cw*12 | ||
| SP7 | +77.2 | + | + | A | 41.5 | F | 1.65 | A*0202, A*3003/*3003 | B*4501, B*5801, Bw*4, Bw*6 | Cw*0701, Cw*1601 | ||
| SP8 | +16.4 | + | + | D | 55.5 | F | 3.19 | A*0201, A*6802 | B*63, B*72 | Cw*02, Cw*14 | ||
| SP9 | +22.7 | + | + | + | D | 36.5 | F | 3.64 | A*0101, A*0301 | B*4415, B*5701, Bw*4 | Cw*0701, Cw*1801 | |
| SP10 | +22.6 | + | + | + | + | nd | 37.5 | F | 1.65 | A*3002, A*7401/02/03 | B*49, B*5703 | Cw*0701/05/06 |
| SP11 | +49.1 | nd | 25.9 | F | 3.97 | A*0101, A*3001 | B*4201, B*5801, Bw*4/*6, Bw*6 | Cw*10, Cw*17 | ||||
| SP12 | +44.8 | + | + | D/B | 31.1 | F | 3.78 | A*3001, A*6602 | B*1801, B*67, Bw*1 | Cw*0704, Cw*1203 | ||
| SP13 | +19.0 | + | + | + | A | 34.5 | M | 4.20 | A*0201/*0209, A*3002/*3003 A*30 | B*5701, B*72, Bw*4, Bw*6 | Cw*0202, Cw*1801 | |
| SP14 | +54.5 | nd | 42.2 | F | 4.95 | A*0201/*0209 | B*4201, B*4501, Bw*6 | Cw*1601, Cw*1701 | ||||
Table 2 illustrates study participant demographics and IFNγ response to clades A, B, C and D gag peptides. CD4+ T –cell slopes were derived from multilevel regression analysis of retrospective 6-monthly CD4+ T-cell counts. Under annual CD4 slope, symbol (−) indicates model-derived decreasing CD4 slopes while (+).indicates decreasing CD4 slopes over time. Under Gag-induced IFN-γ, areas marked + indicate induction of Gag-induced IFN-γ responses to the respective clade of Gag peptides, blank areas indicate lack of IFN-γ response. Clade of the infecting HIV virus was determined from partial sequences of the Gag region, “nd” indicates not done. Bold highlights indicate HLA alleles that have been reported to confer protection from HIV disease.